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TO THE EDITOR—We read with great inter-
est the brief report of a case of allergic
bronchopulmonary aspergillosis (ABPA)
in a human immunodeficiency virus
(HIV)/acquired immune deficiency syn-
drome (AIDS)-infected patient on com-
bined antiretroviral therapy (cART) by
Galiatsatos et al [1]. Allergic bronchopul-
monary aspergillosis usually complicates
lung disease in patients affected by cystic
fibrosis (CF) or asthma. The association
of ABPA with other lung disease such
as chronic obstructive pulmonary disease,
bronchiectasis, Kartagener’s syndrome,
chronic granulomatous disease, and
hyper-immunoglobulin (Ig)E syndrome
has been suggested but not confirmed
[2, 3]. The diagnosis of ABPA in Galiat-
satos’s [1]patient satisfied recent criteria
proposed by Agarwal [2]: presence of
predisposing condition (asthma), 2 of
2 obligatory criteria (total IgE > 1000
IU/mL, elevate IgE levels against Asper-
gillus fumigatus) and 2 of 3 additional
criteria (radiological findings, eosino-
philia) [4].
It is interesting to note that in the dis-
cussion, the authors share important
insights on the still poorly explored field
of ABPA development in patients with
HIV infection. More specifically, they
suggest the possible existence of a hyper-
active immune response contributing to
the development of ABPA in AIDS pa-
tient on cART and with controlled HIV
infection [1]. Although such a possibility
is highly suggestive, we think the presence
of some genetic mutations should also be
investigated, which might explain per se
the development of ABPA in this patient.
Indeed, the reported clinical picture of
ABPA with bronchiectasis, a major phe-
notypic feature of CF, impose an appro-
priate investigation of milder forms of
CF (with normal pancreatic function)
[5]. Moreover, the presence of other Cys-
tic Fibrosis Transmembrane conductance
Regulator (CFTR)-related disorders
should also be ruled out. In this regard,
the frequency of ABPA was much higher
in patients with these disorders rather
than in the general population (67% vs
4%, respectively) [6].
In conclusion, we thank the authors
for sharing this very peculiar case.
Further studies are needed to enrich our
understanding of any possible association
between ABPA and HIV infection and to
better define and weigh the role of CFTR
mutations against this backdrop.
Acknowledgments
Potential conflicts of interest. All authors:
No reported conflicts. All authors have submitted
the ICMJE Form for Disclosure of Potential
Conflicts of Interest.
Emanuele Delfino, Antonio Di Biagio,
Daniele Roberto Giacobbe, and Claudio Viscoli
Infectious Diseases Division, University of Genoa
(Dipartimento di Scienze della Salute) and Istituto di Ricovero e
Cura a Carattere Scientifico San Martino-Istituto Scientifico
Tumori, Genoa, Italy
References
1. Galiatsatos P, Melia MT, Silhan LL. Human immuno-
deficiency virus and allergic bronchopulmonary
aspergillosis: case report and review of literature.
Open Forum Infect Dis 2016; 3:ofw116.
2. Agarwal R, Hazarika B, Gupta D, et al. Aspergillus
hypersensitivity in patients with chronic obstructive
pulmonary disease: COPD as a risk factor for
ABPA? Med Mycol 2010; 48:988–94.
3. Sharma B, Sharma M, Bondi E, Sharma M.
Kartagener’s syndrome associated with allergic bron-
chopulmonary aspergillosis. MedGenMed 2005; 7:25.
4. Agarwal R, Chakrabarti A, Shah A, et al. Allergic
bronchopulmonary aspergillosis: review of literature
and proposal of new diagnostic and classification cri-
teria. Clin Exp Allergy 2013; 43:850–73.
5. Nick JA, Nichols DP. Diagnosis of adult patients with
cystic fibrosis. Clin Chest Med 2016; 37:47–57.
6. Lebecque P, Pepermans X, Marchand E, et al. ABPA
in adulthood: a CFTR-related disorder. Thorax 2011;
66:540–1.
Received 10 August 2016; accepted 17 August 2016.
Correspondence: E. Delfino, IRCCS San Martino University
Hospital-IST, University of Genoa, Largo R. Benzi, Genoa 10-
16132, Italy (emanueledelfino@yahoo.it).
Open Forum Infectious Diseases®
© The Author 2016. Published by Oxford University Press on
behalf of the Infectious Diseases Society of America. This is
an Open Access article distributed under the terms of the
Creative Commons Attribution-NonCommercial-NoDerivs
licence (http://creativecommons.org/licenses/by-nc-nd/4.0/),
which permits non-commercial reproduction and distribution of
thework, in anymedium, provided theoriginalwork is not altered
or transformed in anyway, and that thework is properly cited. For
commercial re-use, please contact journals.permissions@oup.
com. DOI: 10.1093/ofid/ofw192
CORRESPONDENCE • OFID • 1
